How Aging Disrupts Liver Ammonia Processing and Accelerates Systemic Decline
Aging impairs the liver's ability to clear ammonia, triggering mitochondrial damage, cellular senescence, and organ-wide dysfunction.
Summary
Your liver constantly clears ammonia, a toxic byproduct of protein breakdown and gut bacteria. This review in Aging Cell asks whether that job gets worse with age and whether the resulting ammonia buildup speeds up aging itself. The authors lay out how the liver normally handles ammonia, using the urea cycle in one zone and glutamine synthesis in another. They then describe how aging could undermine both systems through mitochondrial decline, chemical modification of key enzymes, loss of the liver's organized zones, and accumulation of senescent cells. Ammonia may also act as a stress signal that promotes cellular senescence, inflammation, and scarring. The authors say direct proof in healthy aging is still missing, so this is a hypothesis-generating framework. It points toward future work on ammonia-lowering drugs, senescence-targeting therapies, and gut-focused approaches.
Detailed Summary
The liver clears ammonia, a neurotoxic byproduct of amino acid breakdown, gut bacterial activity, and nucleotide turnover. Aging research has focused heavily on glucose and lipid metabolism, but nitrogen handling has received far less attention. This narrative review by Zhang, Liang, and Liu in Aging Cell synthesizes the available evidence and proposes ammonia metabolism as an underappreciated axis of liver aging. It is not a systematic review and reports no pooled sample sizes or effect sizes.
The authors first describe a two-tier clearance system. Periportal hepatocytes run the urea cycle, whose rate-limiting step is mitochondrial carbamoyl phosphate synthetase 1 (CPS1) and which depends on ATP. Perivenous hepatocytes express high-affinity glutamine synthetase (GS), which scavenges residual ammonia. Glutaminase also produces ammonia inside the liver. GLS2 is the normal periportal isoform, while GLS1 is induced by stress or senescence.
Next, the review catalogs aging changes that could strain this system. These include hepatocyte enlargement, lipofuscin accumulation, and sinusoidal pseudocapillarization, meaning a thickened endothelium that has lost its fenestrations. Senescent hepatocytes secrete inflammatory SASP factors, and mitochondrial dysfunction and oxidative stress build up. Single-cell transcriptomics suggest aging blurs metabolic zonation, possibly through altered Wnt/β-catenin signaling, and may produce hybrid "bizonal" hepatocytes.
At the enzyme level, multi-omics data show a broad decline in metabolic protein abundance rather than selective loss of urea cycle genes. In rodents, ARG1 protein and activity fall with age even as its mRNA rises. Total CPS1 protein may stay stable, yet its function appears suppressed by increased O-GlcNAcylation. In MASLD, senescent hepatocytes show epigenetic and metabolic reprogramming that suppresses CPS1 and OTC.
Glutamine metabolism may shift too. Senescent cells upregulate GLS1. In one study, lysosomal damage induced the KGA isoform, and the resulting ammonia neutralized intracellular acidosis and helped senescent cells survive. A reported "hyperglutaminolysis" state fuels arginine biosynthesis and sustained mTORC1 activation, accelerating senescence. However, GLS1 inhibition as a senolytic strategy has produced inconsistent results across laboratories. GS expression often falters in chronic liver injury. Beyond detoxification, the abstract describes ammonia as a stress signal tied to mitochondrial injury, proteostasis defects, inflammation, and fibrosis, with downstream effects along the liver–brain, liver–muscle, and liver–gut axes. It also evaluates ammonia-lowering agents, senotherapeutics, and microbiota-directed approaches.
The authors repeatedly stress that direct experimental evidence in healthy physiological aging is limited. Much of the argument is extrapolated from advanced liver disease, MASLD, rodent models, and general mitochondrial decline. A causal link between ammonia dysmetabolism and aging remains unproven, so the review is best read as a roadmap for future mechanistic and human validation work.
Key Findings
- Hepatic ammonia clearance relies on two sequential systems: the periportal urea cycle (CPS1 rate-limiting step) and perivenous high-affinity glutamine synthetase (GS).
- Multi-omics data show a global decline in metabolic enzyme protein abundance with age, not selective urea cycle suppression, and protein loss often occurs without matching transcript changes.
- In aged rodents, ARG1 protein and enzymatic activity decline progressively despite a compensatory rise in ARG1 mRNA.
- CPS1 total protein may remain stable with age, but its activity is suppressed in aged liver through increased O-GlcNAcylation.
- In MASLD, senescent hepatocytes show epigenetic and metabolic reprogramming that suppresses CPS1 and OTC, offering a possible model of accelerated liver aging.
- Senescent cells upregulate GLS1/KGA; the resulting ammonia buffers lysosomal acidosis and supports senescent cell survival, and a reported hyperglutaminolysis state sustains mTORC1 activation to accelerate senescence.
- The senolytic value of GLS1 inhibition is disputed, with recent cross-laboratory studies reporting inconsistent outcomes.
Methodology
This is a narrative (non-systematic) review of the literature on hepatic ammonia metabolism, liver aging, senescence, and ammonia-related organ crosstalk. It reports no new data, pooled sample size, or statistical analysis. Evidence is drawn from rodent studies, multi-omics and single-cell datasets, cell models, and liver disease cohorts such as MASLD. The authors state that many of the proposed age-related changes are inferred from these sources rather than directly validated in healthy aging.
Study Limitations
The authors acknowledge that direct experimental evidence for altered ammonia metabolism in physiological aging is limited and largely extrapolated from liver disease, rodent models, and general mitochondrial decline. Human cohort validation is lacking, and the causal link between ammonia dysmetabolism and aging is unproven. Findings on GLS1 inhibition are inconsistent across laboratories. No conflicts of interest were identified in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: